Shared on 31 Oct 25
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
Shared on 17 Oct 25
Fair value Decreased 0.28%Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
Shared on 03 Oct 25
Fair value Decreased 1.16%Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
Shared on 04 Sep 25
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
Shared on 07 May 25
Fair value Increased 6.23%Syndromic Diagnostics And Automation Will Shape Future Healthcare
Shared on 30 Apr 25
Fair value Decreased 0.66%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Increased 0.12%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 0.62%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.64%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget has decreased revenue growth from 6.3% to 5.4%.
Shared on 02 Apr 25
Fair value Decreased 6.81%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 8.71%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 0.44%Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.